June 8, 2017August 24, 2022
Keytruda Improves Survival in Advanced Melanoma Patients Compared to Yervoy, Phase 3 Trial Shows
News
Patients with unresectable or metastatic melanoma who were treated with Keytruda (pembrolizumab) in a pivotal clinical trial showed superior and sustained time ... Read more
June 6, 2017
New Evidence Presented on Accuracy of DecisionDx-Melanoma Prognosis Test
News
Castle Biosciences presented three abstracts on the validity of using its 31-Gene Expression Profile (GEP) Test for melanoma prognosis at the ... Read more
June 1, 2017June 2, 2017
Biothera to Present Detailed Design of Combo Therapy Study for Melanoma, Breast Cancer
News
Biothera Pharmaceuticals will present the detailed study design of the IMPRIME-1 clinical trial at the upcoming 2017 ASCO Annual Meeting June 2-6 in ... Read more
May 30, 2017
Researchers Provide New Insights into Melanoma Immune Resistance
News
A new study presents detailed information into the processes used by cancer cells to evade and resist the immune response. Researchers studied ... Read more
May 25, 2017May 25, 2017
New Clinical Trial Underway for Treatment of Advanced Melanoma
News
A new clinical trial is underway assessing the addition of the first-in-class AXL kinase inhibitor, BGB324, to standard of care treatment for patients with ... Read more
May 23, 2017May 23, 2017
Skin Cancer Awareness Month Brings Sun Safety to Schools
News
Educating people of all ages, particularly children, about the dangers of sun exposure is urgent to preventing the increased prevalence ... Read more
May 18, 2017
First Patient Enrolled in ONCOS-102, Keytruda Combo Trial for Advanced Melanoma
News
The first patient has been enrolled in Targovax‘s pilot clinical trial for advanced or unresectable melanoma patients whose cancer progressed after treatment ... Read more
May 16, 2017
ImmunoPulse IL-12 and Keytruda Combo Therapy to be Tested in Phase 2 Trial
News
The combination of ImmunoPulse IL-12 and the anti-PD-1 therapy Keytruda (pembrolizumab) soon will be tested in a Phase 2 trial for treatment ... Read more
May 11, 2017
Binimetinib Improves Progression-free Survival of Certain Melanoma Patients in Phase 3 Trial
News
Adding the small molecule MEK inhibitor binimetinib to the BRAF inhibitor encorafenib was safe and significantly prolonged the time to disease progression ... Read more
May 9, 2017May 9, 2017
Melanoma Scientist Among 6 in NYC Awarded Prestigious Research Prize
News
The Pershing Square Sohn Cancer Research Alliance has announced the six winners of the fourth edition of the annual Pershing ... Read more
May 4, 2017
Castle’s Gene Test Shows Accuracy in Predicting Recurrence, Spread of Head and Neck Melanoma
News
Castle Biosciences’ DecisionDx-Melanoma test can be used to accurately predict cancer recurrence and metastasis in patients with head and neck melanoma, ... Read more
April 25, 2017
IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group
News
Prima Biomed, an Australian biotechnology company developing immunotherapies for cancer and autoimmune diseases, announced it has received approval for the ... Read more

October 20, 2015October 22, 2015

‘Mole Mapper’ iPhone App to Aid Understanding of Melanomas in Research Study

News

Seattle, Washington-based, nonprofit biomedical research organization Sage Bionetworks, in collaboration with Oregon Health & Science University (OHSU) and National Cancer Institute cancer biologist Dan Webster, PhD, has announced the launch of ... Read more

October 15, 2015October 22, 2015

Dr. Alberto Pappo Interviewed About Pediatric Melanoma

News

Estimates indicate that each year in the United States, there are about 400 new diagnosis of melanoma among those younger than 19 years of age. According to the St. Jude Children’s ... Read more

October 13, 2015October 13, 2015

Opdivo/ Yervoy Regimen Receives FDA Approval for BRAF V600 Wild-Type Unresectable or Metastatic Melanoma

News

Bristol-Myers Squibb Company announced it has received US Food and Drug Administration (FDA) approval for the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) in the treatment of patients diagnosed with BRAF V600 wild-type unresectable or metastatic melanoma ... Read more

October 1, 2015October 13, 2015

Arteries Are Better Than Veins for Liquid Biopsy, According to Study

News

Researchers from Thomas Jefferson Medical School (TJMS), Philadelphia, have recently released study findings which may hold important implications for a novel test currently approved for use to detect circulating tumor ... Read more

September 24, 2015September 24, 2015

NICE Approves Keytruda for Melanoma

News

Melanoma patients in England who have ceased responding to standard-of-care treatments can soon avail of a new immunotherapy drug that works by “unmasking” cancer cells and reprogramming the body’s immune system ... Read more

September 22, 2015September 25, 2015

Novel Discoveries May Hold Answers For Treatment-Resistant Melanoma

News

UCLA scientists have recently released study findings which may hold important implications in the field of metastatic melanoma research. The study entitled, “Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance“, ... Read more

September 17, 2015September 17, 2015

Immune Irregularities May Increase Melanoma Risk Among Certain Non-Hodgkin’s Lymphoma Survivors

News

A collaborative team of interdisciplinary researchers led by Clara J.K. Lam, MPH, a predoctoral fellow in the Radiation Epidemiology Branch of the National Cancer Institute (NCI) and PhD student in cancer ... Read more

September 15, 2015September 15, 2015

Adding Aspirin to Cancer Immunotherapy Slows Tumor Growth in Mice

News

A multidisciplinary team of researchers from the Francis Crick Institute, with funding from Cancer Research UK, have recently released results that could advance immunotherapy treatment options for certain cancers, such as ... Read more

September 10, 2015September 15, 2015

EMA Accepts Immunocore’s IMCgp100 for Adaptive Pathway Pilot Program In Melanoma

News

Immunocore Limited, one of the world’s leading biotechnology companies with a highly innovative immuno-oncology platform technology called ImmTACs, has just announced its lead product candidate, IMCgp100, has been accepted by the European Medicines ... Read more

September 3, 2015September 3, 2015

Researchers Identify Novel Mutation in Melanoma Cancer Cells

News

In a recent study published in Science Signaling entitled “The E3 ligase APC/CCdh1 promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth“, scientists from the Boston University School ... Read more

September 1, 2015September 14, 2015

SciBase US Reader Study for Nevisense Arrives at Positive Results, Improves Melanoma Diagnoses Accuracy

News

SciBase AB, a Swedish medical technology company headquartered in Stockholm, has recently announced the results of its US Reader Study. According to SciBase, the addition of Nevisense, which uses Electrical Impedance Spectroscopy ... Read more

August 28, 2015August 28, 2015

Not All Dermatology Treatments Are Necessary, According to The American Academy of Dermatology

News

The American Academy of Dermatology has recently updated its recommendations on a wide variety of dermatologic tests and treatments that may not be medically necessary. Costly tests are sometimes done on patients with ... Read more

Keytruda Improves Survival in Advanced Melanoma Patients Compared to Yervoy, Phase 3 Trial Shows

New Evidence Presented on Accuracy of DecisionDx-Melanoma Prognosis Test

Biothera to Present Detailed Design of Combo Therapy Study for Melanoma, Breast Cancer

Researchers Provide New Insights into Melanoma Immune Resistance

New Clinical Trial Underway for Treatment of Advanced Melanoma

Skin Cancer Awareness Month Brings Sun Safety to Schools

First Patient Enrolled in ONCOS-102, Keytruda Combo Trial for Advanced Melanoma

ImmunoPulse IL-12 and Keytruda Combo Therapy to be Tested in Phase 2 Trial

Binimetinib Improves Progression-free Survival of Certain Melanoma Patients in Phase 3 Trial

Melanoma Scientist Among 6 in NYC Awarded Prestigious Research Prize

Castle’s Gene Test Shows Accuracy in Predicting Recurrence, Spread of Head and Neck Melanoma

IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group